Nicotinamide and Pyruvate for Open Angle Glaucoma: a Randomized Clinical Study

Description

The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).

Conditions

Primary Open Angle Glaucoma

Study Overview

Study Details

Study overview

The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N\&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma. A total of up to 188 participants will be enrolled and randomized 1:1 to receive N\&P or placebo for 87 weeks (20 months). Participants will be followed for a total of 91 weeks (21 months).

Nicotinamide and Pyruvate for Open Angle Glaucoma: a Randomized Clinical Study

Nicotinamide and Pyruvate for Open Angle Glaucoma: a Randomized Clinical Study

Condition
Primary Open Angle Glaucoma
Intervention / Treatment

-

Contacts and Locations

New York

ColumbiaDoctors Ophthalmology - 880 Third Avenue, New York, New York, United States, 10022

New York

Columbia University Irving Medical Center - 622 W 168th St, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    35 Years to 85 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Columbia University,

    Aakriti G. Shukla, MD, PRINCIPAL_INVESTIGATOR, Columbia University

    Study Record Dates

    2028-01